Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(02)03684-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study of Pharmacokinetics for Ivermectin B1a from Beagle Dogs.
J Chromatogr Sci
December 2023
School of Pharmacy, Guangzhou Medical University, Xinzao, Panyu District, Guangzhou, Guangdong 511436, China.
Ivermectin has been widely used for antiparasitic drug, and has recently shown a broad-spectrum antiviral activity, including anti-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the pharmacokinetic property of ivermectin has not been fully investigated yet. During the plasma preparation, ~32-46% of ivermectin was found in the precipitation.
View Article and Find Full Text PDFEffect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of sunitinib in rats.
Drug Metab Dispos
August 2013
Department of Pharmacy, Kyoto University Hospital, Sakyo-ku, Kyoto 606-8507, Japan.
The aim of this study was to elucidate the roles of P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) in the plasma concentration, biliary excretion, and distribution to the liver, kidney, and brain of sunitinib. The pharmacokinetics of sunitinib was examined in rats treated with PSC833 (valspodar) and pantoprazole, potent inhibitors of P-gp and BCRP, respectively. The sunitinib concentrations in plasma, bile, liver, kidney, and brain were determined by liquid chromatography-tandem mass spectrometry.
View Article and Find Full Text PDFLongitudinal evaluation of mycophenolic acid pharmacokinetics in pediatric kidney transplant recipients. The role of post-transplant clinical and therapeutic variables.
Clin Transplant
July 2009
Pediatric Nephrology Unit, Maggiore Policlinico Hospital, Mangiagalli and Regina Elena Foundation, IRCCS, Milan, Italy.
This longitudinal study assessed the influence of post-transplant clinical and therapeutic variables in 50 kidney transplant recipients aged 2-19 yr receiving a triple immunosuppressive regimen consisting of cyclosporine microemulsion (CsA), steroids and MMF (300-400 mg/m(2) body surface area twice daily), the full pharmacokinetic profile (10 points) of which was investigated on post-transplant days 6, 30, 180 and 360. Total plasma MPA was measured by Enzyme Multiplied Immunoassay Technique. CsA therapeutic drug monitoring (TDM) was performed via C2 blood monitoring, while MPA TDM via C0.
View Article and Find Full Text PDFRole of metabolites and calcineurin inhibition on C2 monitoring in renal transplant patients.
Nephrol Dial Transplant
March 2005
Research Laboratory, Department of Renal Medicine C, Skejby Sygehus, Arhus University Hospital, Arhus, Denmark.
Background: Many transplantation centres have switched to C2 monitoring of cyclosporin-treated renal transplant patients. The rationale is that the C2 correlates best with AUC0-4 (area under the concentration-time curve), which again correlates with rejection and nephrotoxicity. It has also been demonstrated that calcineurin phosphatase is inhibited maximally 1-2 h after intake of cyclosporin in patients receiving their first dose.
View Article and Find Full Text PDFThe roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients.
Transplant Proc
December 2002
Division of Nephrology, Department of Medicine, Chulalongkorn University Hospital, Bangkok, Thailand.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!